LENZ Therapeutics, Inc. Common Stock

LENZNASDAQ • USD
ThemeBiotech - Drug Development›Clinical-Stage Platforms
5.52 USD
↘ 0.07 (1.25%)🔴AT CLOSE (AS OF 07:47 PM EDT)
🔴Market: CLOSED

Shares of LENZ Therapeutics, Inc. Common Stock (LENZ) are trading at $5.52. Technical and fundamental signals converge bearish — technicals rate "Strong Sell" while fundamentals read "Sell". Notable factors include a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation metrics place LENZ at a fair price relative to peers.

Technical & fundamental data as of Jun 25, 2026.

Open?$5.63
High?$5.72
Low?$5.23
Prev. Close?$5.58
Volume?1.1M
Avg. Volume?780.2K
VWAP?$5.41
Rel. Volume?1.37x
Bid / Ask
Bid?$5.03 × 200
Ask?$5.84 × 100
Spread?$0.81
Midpoint?$5.44
Valuation & Ratios
Market Cap?175.0M
Shares Out?31.4M
Float?18.3M
Float %?58.3%
P/E Ratio?N/A
P/B Ratio?0.71
EPS?-$3.47
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
Themes
Biotech - Drug Development›Clinical-Stage PlatformsLongevity & Aging›Age-Related Therapeutics
Employees
152
Market Cap
175.0M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.lenz-tx.com
Listed
2024-03-22
Address
201 LOMAS SANTA FE DRIVE, SUITE 300
SOLANA BEACH, CA 92075
Phone: 858-925-7000
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
49
Momentum?
18
Short Sent.?
30
Piotroski F-Score?0/9Weak
Altman Z-Score?2.36Grey
Confidence?52%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?56.82%Squeeze Risk
Short Interest?10.4M
Days to Cover?20.3
Free Float18.3M
Avg Daily Volume510.9K
Settlement Date2026-06-15
Financial Health
Current Ratio?10.40Strong
Quick Ratio?10.26Strong
Cash Ratio?0.96Adequate
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
Peers
100
S&P
97
0.71CHEAP▾
P/S?
Peers
100
S&P
12
8.34HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-1.3CHEAP▾
EV/Sales?
Peers
100
S&P
19
7.16HIGH▾
Returns & Efficiency
ROE?
S&P
3
-44.2%WEAK▾
ROA?
S&P
3
-40.0%WEAK▾
Cash Flow & Enterprise
FCF?$-87438000
Enterprise Value?$150.2M
Fundamentals ratios updated end of day
MarketsMoversWatchlist